IFP Advisors
FDMT icon

IFP Advisors’s 4D Molecular Therapeutics FDMT Stock Holding History

IFP Advisors’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.12K Hold
78
– – ﹤0.01% 4460
2026
Q2 		$1.04K Hold
78
– – ﹤0.01% 4483
2026
Q1 		$726 Hold
78
– – ﹤0.01% 4322
2025
Q4 		$585 Hold
78
– – ﹤0.01% 4245
2025
Q3 		$678 Buy
+78
New +$466 ﹤0.01% 4085
2025
Q2 		– Hold
0
– – – 4423
2025
Q1 		– Hold
0
– – – 4281
2024
Q4 		– Hold
0
– – – 4554

Other funds holding FDMT

Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Perigon Wealth Management
Perigon Wealth Management San Francisco, California $6.5B AUM 20.72% 1-Year Est. Return
Hussman Strategic Advisors
Hussman Strategic Advisors Ellicott City, Maryland $469M AUM 10.16% 1-Year Est. Return
Privium Fund Management
Privium Fund Management Amsterdam, Netherlands $516M AUM 18.66% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
ALPS Advisors
ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $87.8B AUM 20.94% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $64.1B AUM 28.9% 1-Year Est. Return

IFP Advisors's FDMT Position: Q3 2026 in Review

IFP Advisors held its 4D Molecular Therapeutics (FDMT) position steady in Q3 2026 at 78 shares worth $1.12K. The position accounts for ﹤0.01% of the portfolio, ranked #4460.

IFP Advisors first reported a position in FDMT in Q3 2025 and has held it in 5 quarters since. 45 funds tracked by Wall St. Rank hold FDMT as of Q3 2026.

  • IFP Advisors held 78 shares of 4D Molecular Therapeutics worth $1.12K as of Q3 2026.
  • IFP Advisors left its 4D Molecular Therapeutics share count unchanged in Q3 2026.
  • 4D Molecular Therapeutics made up ﹤0.01% of IFP Advisors's portfolio in Q3 2026, its #4460 holding.
  • IFP Advisors first reported a position in 4D Molecular Therapeutics in Q3 2025 and has held it in 5 quarters since.
  • 45 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q3 2026.

Based on IFP Advisors's 13F filing for Q3 2026, filed 16 Oct 2026.